Adding Radioligand Therapy Pluvicto to SOC Cuts Risk of Prostate Cancer Progression or Death 28%, but How Many Doses?

Combining the radioligand therapy lutetium (¹⁷⁷Lu) vipivotide tetraxetan, or ¹⁷⁷Lu-PSMA-617, with androgen deprivation therapy (ADT) and androgen receptor pathway inhibitor (ARPI) therapy reduced the risk of progression or death by 28% for…